| abstract |
Human antibodies that bind the C-terminal domain of Apolipoprotein E (ApoE) and that also bind human plaques are disclosed. Also disclosed are human antibodies that bind ApoE C-terminal domain in the presence of very low density lipoprotein (VLDL). Antibody heavy chain and light chain sequences are also provided, and the antibodies that can be generated from these sequences may bind ApoE C-terminal domain and/or may bind human plaques. The antibodies can b used for the treatment or prevention of amyloid disorders such as Alzheimer's disease or Creutzfeldt-Jakob disease. |